Stay updated on HER2/EGFR Mutant Tumors Clinical Trial

Sign up to get notified when there's something new on the HER2/EGFR Mutant Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HER2/EGFR Mutant Tumors Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changed from v3.8.0 to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-21T15:27:01.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.0%
    Check dated 2026-10-31T15:54:20.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A banner announces upcoming changes to NIH websites and notes that agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”
    Difference
    0.3%
    Check dated 2026-10-24T16:53:57.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision advances from v3.7.1 to v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-17T16:42:16.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.0%
    Check dated 2026-10-10T17:03:47.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    The record history now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a software version update for the history view rather than any changes to study data or text.
    Difference
    0.0%
    Check dated 2026-09-19T22:25:10.000Z thumbnail image

Stay in the know with updates to HER2/EGFR Mutant Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HER2/EGFR Mutant Tumors Clinical Trial page.